Am J Hematol
- SHORT NJ, Jabbour E, Nasr LF, Jain N, et al
Characteristics and outcomes of patients with relapsed Philadelphia
chromosome-positive acute lymphoblastic leukemia after failure of a frontline
ponatinib-containing therapy.
Am J Hematol. 2024 Apr 12. doi: 10.1002/ajh.27329.
- SHOMALI W, Gotlib J
World Health Organization and International Consensus Classification of
eosinophilic disorders: 2024 update on diagnosis, risk stratification, and
management.
Am J Hematol. 2024;99:946-968.
- CIUREA SO, Kongtim P, Srour S, Chen J, et al
Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells
for patients with multiply relapsed and refractory AML.
Am J Hematol. 2024;99:890-899.
- ORVAIN C, Ali N, Othus M, Rodriguez-Arboli E, et al
Relative prognostic value of flow cytometric measurable residual disease before
allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML.
Am J Hematol. 2024;99:862-870.
- NISHIWAKI S, Sugiura I, Fujisawa S, Hatta Y, et al
Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete
molecular remission.
Am J Hematol. 2024;99:806-815.
Ann Hematol
- GU Z, Li F, Li M, Wang L, et al
Upfront allogeneic hematopoietic stem cell transplantation for adult T-cell acute
lymphoblastic leukemia/lymphoma in first complete remission: a single-center
study.
Ann Hematol. 2024 Apr 12. doi: 10.1007/s00277-024-05716.
- LUO L, Jiao Y, Li Y, Yang P, et al
Efficacy and prognostic factors of allogeneic hematopoietic stem cell
transplantation treatment for adolescent and adult Tlymphoblastic leukemia
/lymphoma: a large cohort multicenter study in China.
Ann Hematol. 2024 Apr 6. doi: 10.1007/s00277-024-05719.
Blood
- BULLINGER L, Kronke J
Making AML fly too close to the sun.
Blood. 2024;143:1438-1439.
- BOURGEOIS W, Cutler JA, Aubrey BJ, Wenge DV, et al
Mezigdomide is effective alone and in combination with menin inhibition in
preclinical models of KMT2A-r and NPM1c AML.
Blood. 2024;143:1513-1527.
Bone Marrow Transplant
- BARANWAL A, Mangaonkar A, Shah MV, Al-Kali A, et al
EASIX and CPSS Cytogenetics score-based composite risk model for patients with
CMML undergoing allogeneic transplant.
Bone Marrow Transplant. 2024;59:558-560.
- FILIOGLOU D, Truscott L, Reddivalla N, Katsanis E, et al
Outcomes of haploidentical bone marrow transplantation in infant acute leukemia:
a single center experience.
Bone Marrow Transplant. 2024 Apr 9. doi: 10.1038/s41409-024-02281.
Br J Haematol
- LIGIA S, Passucci M, Assanto GM, D'Elia GM, et al
Early clearance of hairy cell leukaemia in the bone marrow after first-line
treatment with cladribine predicts a favourable outcome.
Br J Haematol. 2024;204:1288-1292.
- MADERO-MARROQUIN R, DuVall AS, Saygin C, Wang P, et al
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH
inhibitors.
Br J Haematol. 2024;204:1238-1242.
- ROY MOULIK N, Keerthivasagam S, Pandey A, Agiwale J, et al
Treatment and follow-up of children with chronic myeloid leukaemia in chronic
phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of
experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
Br J Haematol. 2024;204:1249-1261.
- LIANG P, Xie Y, Liu Z, Wang D, et al
Venetoclax and hypomethylating agents in critically ill patients with newly
diagnosed acute myeloid leukaemia.
Br J Haematol. 2024;204:1219-1226.
- FIEDLER W
Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed
acute myeloid leukaemia requiring admission to the intensive care unit: Possible
reduction in side effects with preserved efficacy.
Br J Haematol. 2024;204:1135-1136.
- SUWANNAYING K, Ong AA, Dhaduk R, Pei D, et al
Quantitative computed tomography analysis of body composition changes in
paediatric patients with acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1335-1343.
- ZUCENKA A, Griskevicius L
Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin
D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
Br J Haematol. 2024;204:1227-1231.
- NACHMIAS B, Aumann S, Haran A, Schimmer AD, et al
Venetoclax resistance in acute myeloid leukaemia-Clinical and biological
insights.
Br J Haematol. 2024;204:1146-1158.
- JOHNSON IM, Karrar O, Rana M, Iftikhar M, et al
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with
venetoclax + hypomethylating agents.
Br J Haematol. 2024;204:1232-1237.
- ALCAZER V, Morisset S, Rea D, Legros L, et al
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in
chronic phase chronic myelogenous leukaemia patients.
Br J Haematol. 2024;204:1536-1539.
- ZHANG T, Zhang Y, Zhou M, Zhang Z, et al
Risk factors and survival analysis of human leukocyte antigen loss in relapsed
acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic
haematopoietic stem cell transplantation.
Br J Haematol. 2024;204:1402-1413.
- PATEL SA
The heart of VIALE-A: Cardiac complications of hypomethylating agents and
venetoclax in acute myeloid leukaemia.
Br J Haematol. 2024;204:1137-1138.
- STENTOFT J
The Mozart effect in chronic myeloid leukaemia.
Br J Haematol. 2024;204:1139-1140.
- MOSQUERA ORGUEIRA A, Perez Encinas MM, Diaz Varela N, Wang YH, et al
Validation of the Artificial Intelligence Prognostic Scoring System for
Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach
for improved risk stratification.
Br J Haematol. 2024;204:1529-1535.
- CHEN X, Li J, Yu L, Hu W, et al
High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric
acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
Br J Haematol. 2024;204:1354-1366.
- BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
Relevance of CD20 antigen expression among paediatric patients with B-lineage
acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1367-1374.
- LIU HC, Huang YJ, Jaing TH, Wu KH, et al
Refining risk stratification in paediatric B-acute lymphoblastic leukaemia:
Combining IKZF1(plus) and Day 15 MRD positivity.
Br J Haematol. 2024;204:1344-1353.
Cancer
- JABBOUR E, Haddad FG, Sasaki K, Carter BZ, et al
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic
myeloid leukemia.
Cancer. 2024 Apr 9. doi: 10.1002/cncr.35317.
- LOKE J, Labopin M, Craddock C, Socie G, et al
Prognostic impact of number of induction courses to attain complete remission in
patients with acute myeloid leukemia transplanted with either a matched sibling
or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia
Working Party
Cancer. 2024 Apr 6. doi: 10.1002/cncr.35308.
Cancer Lett
- ZHAO Y, Chen W, Yu J, Pei S, et al
TP53 in MDS and AML: Biological and clinical advances.
Cancer Lett. 2024;588:216767.
Gene
- LIU S, Zhan W, He X, Hao M, et al
ATPR induces acute promyelocytic leukemia cells differentiation and cycle arrest
via the lncRNA CONCR/DDX11/PML-RARalpha signaling axis.
Gene. 2024 Apr 4:148443. doi: 10.1016/j.gene.2024.148443.
Int J Hematol
- IRIYAMA N, Iwanaga E, Kimura Y, Watanabe N, et al
Changes in chronic myeloid leukemia treatment modalities and outcomes after
introduction of second-generation tyrosine kinase inhibitors as first-line
therapy: a multi-institutional retrospective study by the CML Cooperative Study
Group.
Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03758.
Leuk Res
- YIGIT KAYA S, Mutlu YG, Malkan UY, Mehtap O, et al
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment
of relapsed/refractory hairy cell leukemia, a multicenter experience.
Leuk Res. 2024;140:107495.
- MORSY MM, Azzam AY, Elamin O, Elswedy A, et al
Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid
leukemia: A subgroup based meta-analysis.
Leuk Res. 2024;140:107498.
Leukemia
- BELL HL, Blair HJ, Jepson Gosling SJ, Galler M, et al
Combination p53 activation and BCL-x(L)/BCL-2 inhibition as a therapeutic
strategy in high-risk and relapsed acute lymphoblastic leukemia.
Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02241.
- FRUCHTMAN H, Avigan ZM, Waksal JA, Brennan N, et al
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02246.
- MCLORNAN DP, Czerw T, Damaj G, Ethell M, et al
Allogeneic haematopoietic cell transplantation for advanced systemic
mastocytosis: Best practice recommendations on behalf of the EBMT Practice
Harmonisation and Guidelines Committee.
Leukemia. 2024;38:699-711.
- LUBKE J, Christen D, Schwaab J, Kaiser A, et al
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis:
A retrospective analysis of the DRST and GREM registries.
Leukemia. 2024;38:810-821.
- SHIMONY S, Bewersdorf JP, Shallis RM, Liu Y, et al
Hypomethylating agents plus venetoclax compared with intensive induction
chemotherapy regimens in molecularly defined secondary AML.
Leukemia. 2024;38:762-768.
- SEBERT M, Freiman L, Chaffaut C, Guerci A, et al
Clinical impact of genetic alterations including germline DDX41 mutations in
MDS/low-blast count AML patients treated with azacitidine-based regimens.
Leukemia. 2024;38:918-922.
- SEVERENS JF, Karakaslar EO, van der Reijden BA, Sanchez-Lopez E, et al
Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel
clusters and divergent ex-vivo drug responses.
Leukemia. 2024;38:751-761.
Proc Natl Acad Sci U S A
- KRISTENSON L, Badami C, Ljungberg A, Islamagic E, et al
Deletion of the TMEM30A gene enables leukemic cell evasion of NK cell
cytotoxicity.
Proc Natl Acad Sci U S A. 2024;121:e2316447121.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016